<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00865982</url>
  </required_header>
  <id_info>
    <org_study_id>Eudract-CT-2008-001849-26</org_study_id>
    <nct_id>NCT00865982</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Safety and Efficacy of Perioperative Chemotherapy With Docetaxel, Cisplatin and Capecitabine (DCX) in Patients With Gastro-esophageal Cancer</brief_title>
  <acronym>DCXAIOCHARITE</acronym>
  <official_title>Multicenter, Open Lable Phase II Study to Evaluate the Safety and Efficacy of a Perioperative Chemotherapy With Docetaxel, Cisplatin and Capecitabine in Patients With Gastric Adenocarcinoma, Adenocarcinoma of the Gastro-esophageal Junction or the Distal Esophagus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, patients with adenocarcinoma of the stomach, gastro-esophageal junction or the&#xD;
      distal esophagus who seem operable with curative intent according to oncological and surgical&#xD;
      assessment are treated with 3 preoperative cycles of DCX (Docetaxel, Cisplatin, Capecitabine)&#xD;
      followed by surgical resection, followed by 3 postoperative cycles of DCX.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Perioperative chemotherapy has been shown to significantly improve the R0 resection rate, the&#xD;
      disease free survival and the overall survival in patients with adenocarcinoma of the distal&#xD;
      esophagus, the gastro-esophageal junction and the stomach. Therefore perioperative&#xD;
      chemotherapy is the new therapeutic standard (Cunningham NEJM 2006, MRC, Lancet 2002, Boige&#xD;
      ASCO 2007). The best evaluated regime is the combination of Epirubicin, Cisplatin and 5-FU&#xD;
      (ECF) (Cunningham, NEJM 2007). Cisplatin and 5-FU seem to be the most important components&#xD;
      forming the backbone of this regime (Boige ASCO 2007).&#xD;
&#xD;
      Docetaxel is a new and highly active agent in gastric cancer. In a randomized phase II study&#xD;
      the dual combination of Docetaxel and 5-FU seemed to show similar activity as ECF,&#xD;
      administered as first line palliative treatment (Thuss-Patience, JCO, 2005). The three drug&#xD;
      combination Docetaxel, Cisplatin, 5-FU has significantly superior efficacy than a combination&#xD;
      of Cisplatin und 5-FU, superior quality of life and significantly superior overall survival&#xD;
      (Van Cutsem, JCO 2007).&#xD;
&#xD;
      It has been shown that Capecitabine the oral prodrug of 5-FU is similarly active as 5-FU and&#xD;
      can replace intravenous 5-FU in combination with Cisplatin in the treatment of gastric&#xD;
      cancer. Capecitabine therefore is FDA approved for gastric cancer (Cunningham, ASCO 2006,&#xD;
      Kang ASCO 2006).&#xD;
&#xD;
      It seems reasonable to optimize perioperative chemotherapy by including modern&#xD;
      chemotherapeutics. The old standard ECF may be improved by integrating Docetaxel und&#xD;
      Capecitabine. By adding Docetaxel to the Cisplatin / flouropyrimidin backbone the efficacy of&#xD;
      the regime may be improved. The replacement of 5-FU by Capecitabine may improve patients´&#xD;
      convenience and possibly effectiveness of the combination. Therefore the 3 drug combination&#xD;
      of Docetaxel, Cisplatin, Capecitabin (DCX) seems to be a highly promising regime regarding&#xD;
      effectiveness and convenience.&#xD;
&#xD;
      In this study patients with adenocarcinoma of the stomach, gastro-esophageal junction or the&#xD;
      distal esophagus who seem operable with curative intent according to oncological and surgical&#xD;
      assessment are treated with 3 preoperative cycles of DCX followed by surgical resection,&#xD;
      followed by 3 postoperative cycles of DCX.&#xD;
&#xD;
      The first application of study medication has to be within 21 days of tumour assessment.&#xD;
      There will be 3 preoperative cycles every 3 weeks. The experimental perioperative regime&#xD;
      evaluated in this study will be Docetaxel/Cisplatin/Capecitabine DCX (75/ 60/ 1875 mg/m2).The&#xD;
      operation will be performed 3 to 6 weeks after the end of the third preoperative chemotherapy&#xD;
      cycle (counted from day 21 of cycle 3).&#xD;
&#xD;
      Postoperative chemotherapy will start within 6 - 12 weeks after the operation. 3 weeks after&#xD;
      the end of the last chemotherapy the final investigation (end of study visit) will be done.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>September 2008</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>R0-resection rate</measure>
    <time_frame>After 3 cycles of preoperative chemotherapy (3 month)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Remission rate according to diagnostic imaging techniques</measure>
    <time_frame>After 3 cycles of preoperative chemotherapy (3 month)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathological remission rate</measure>
    <time_frame>After 3 cycles of preoperative chemotherapy (3 month)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Operative and postoperative complication rate</measure>
    <time_frame>Within 30 days after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resectability rate</measure>
    <time_frame>After 3 cycles of preoperative chemotherapy (3 month)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of local recurrences and metastasis</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30-day mortality</measure>
    <time_frame>After date of surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival rate</measure>
    <time_frame>1,2,3 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event free survival rate</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Gastric Cancer</condition>
  <condition>Esophageal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel, Cisplatin, Capecitabine</intervention_name>
    <description>3 preoperative cycles with Docetaxel 75 mg/m² d1 Cisplatin 60 mg/m² d1 Capecitabine 1875 mg/m²/day d1-14 repeated every 3 weeks&#xD;
followed by resection&#xD;
and 3 postoperative cycles with Docetaxel 75 mg/m² d1 Cisplatin 60 mg/m² d1 Capecitabine 1875 mg/m²/day d1-14 repeated every 3 weeks.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed and dated consent&#xD;
&#xD;
          -  Age between minimum 18 and maximum 75 years&#xD;
&#xD;
          -  Primary diagnosis of histologically proven adenocarcinoma of the stomach, the&#xD;
             gastro-esophageal junction or an adenocarcinoma of the lower third of the esophagus&#xD;
&#xD;
          -  Stage II-III, which is in TNM-staging: T3-4, N0-3, M0 or T2, N1-3, M0 or T1, N2, M0.&#xD;
             (equivalent to clinical staging uT3-4NXM0, uT1-2N+M0)&#xD;
&#xD;
          -  Intended curative resection according to evaluation of an experienced surgeon&#xD;
&#xD;
          -  Karnofsky-performance-index &gt; 70%&#xD;
&#xD;
          -  Negative pregnancy blood test at screening but not earlier than 72 hours prior to&#xD;
             start of chemotherapy for women with child bearing potential&#xD;
&#xD;
          -  Adequate haematologic function and liver and renal function: neutrophils &gt; 1,5 x&#xD;
             109/L; thrombocytes &gt; 100 x 109/L; haemoglobin &gt; 10 g/dl, creatinine clearance &gt; 60&#xD;
             ml/min (calculated according to Cockroft and Gault), total bilirubin &lt; 1,0 x UNL; AST&#xD;
             and ALT &lt; 1,5 x UNL, AP &lt; 2,5 x UNL&#xD;
&#xD;
          -  Complete staging within 3 weeks prior to start of treatment (CT-scan of thorax and&#xD;
             abdomen, endosonography, gastroscopy)&#xD;
&#xD;
          -  Ability to keep appointments and follow the study protocol&#xD;
&#xD;
          -  By CT-scan, endoscopy or endosonography measurable or evaluable disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Former therapy of gastro-esophageal cancer (operation, chemo- or radiotherapy)&#xD;
&#xD;
          -  Diagnosis of another cancer in the last 5 years prior to study entry which has not&#xD;
             been cured by operation only (exception in-situ-carcinoma of the cervix or cured&#xD;
             non-melanomatose skin cancer)&#xD;
&#xD;
          -  Known dihydropyrimidine-dehydrogenase (DPD)-deficiency&#xD;
&#xD;
          -  Known contraindication to the planned chemotherapeutics&#xD;
&#xD;
          -  Presence of distant metastases&#xD;
&#xD;
          -  Anamnestic known serious disease or other concomitant diseases that affect&#xD;
             participation in this study, such as:&#xD;
&#xD;
               -  Instable cardiac disease: symptomatic heart failure, symptomatic coronary artery&#xD;
                  disease, ventricular cardiac arrhythmia not well controlled with medication,&#xD;
                  myocardial infarction or resuscitation within 6 month before study&#xD;
&#xD;
               -  Active infection necessitating systemic therapy or uncontrolled infection&#xD;
&#xD;
               -  Interstitial lung diseases (for example: pneumonitis or fibrosis of the lung) and&#xD;
                  indication for interstitial lung disease in chest x-ray or CT-scan respectively&#xD;
&#xD;
               -  Active inflammatory bowel disease or other bowel diseases which provoke chronic&#xD;
                  diarrhea (defined as &gt; 4 bowel movements per day)&#xD;
&#xD;
               -  Neurological or psychiatric disease including dementia, epilepsy or untreated,&#xD;
                  symptomatic brain metastases&#xD;
&#xD;
               -  Limited hearing ability&#xD;
&#xD;
          -  Presence of upper GI obstruction, leading to inability to swallow ground tablets&#xD;
&#xD;
          -  Presence of acute or chronic systemic infection&#xD;
&#xD;
          -  Presence of a bowel obstruction within the last 30 days&#xD;
&#xD;
          -  Pregnant or lactating women or women with child bearing potential and men without&#xD;
             adequate contraception (high effective contraception, defined as Pearl Index &lt; 1) like&#xD;
             birth control pill, hormone spiral, hormone implant, transdermal patch, a combination&#xD;
             of two barrier methods (condom and diaphragm), realized sterilization or sexual&#xD;
             abstinence during the study and at least for 3 months after the last infusion&#xD;
&#xD;
          -  Any other situation which may lead to an unacceptable high risk for the patient, when&#xD;
             he participates in the study&#xD;
&#xD;
          -  Parallel treatment in another clinical study or prior participation in this study&#xD;
&#xD;
          -  Treatment with any other therapy against the tumor or any parallel radiation&#xD;
&#xD;
          -  Parallel treatment with Sorivudine or an chemically related substance like for example&#xD;
             Brivudin&#xD;
&#xD;
          -  Symptomatic peripheral neuropathy NCI-CTCAE degree &gt; 2&#xD;
&#xD;
          -  Intolerance to the study medication or their galencic ingredients or against 5-FU&#xD;
&#xD;
          -  Detention in a psychiatric unit or imprisonment (AMG §40 Abs. 1 Nr. 4)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Thuss-Patience, Dr. med.</last_name>
    <role>Study Chair</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HELIOS-Klinik Bad Saarow</name>
      <address>
        <city>Bad Saarow</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Hämatologie, Onkologie und Tumorimmunologie, Charite Campus Buch</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik mit Schwerpunkt Gastroenterologie, Infektiologie und Rheumatologie, Charite Campus Benjamin-Franklin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik mit Schwerpunkt Hämatologie und Onkologie, Charite Campus Virchow Klinikum</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Innere Medizin Abteilung Hämatologie/Onkologie, Städtisches Klinikum Dessau</name>
      <address>
        <city>Dessau</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik und Poliklinik für Innere Medizin IV, Martin Luther Universität Halle-Wittenberg</name>
      <address>
        <city>Halle (Saale)</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>II. Medizinische Klinik und Poliklinik, Universitätsklinikum Schleswig-Holstein Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internistische Onkologie/ Hämatologie, Städtisches Krankenhaus St. Georg</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>3. Medizinische Klinik, Onkologisches Zentrum, Universitätsklinikum Mannheim</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <study_first_submitted>March 19, 2009</study_first_submitted>
  <study_first_submitted_qc>March 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2009</study_first_posted>
  <last_update_submitted>August 4, 2011</last_update_submitted>
  <last_update_submitted_qc>August 4, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 5, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. med. Peter Thuss-Patience</name_title>
    <organization>Charite University, Berlin, Germany</organization>
  </responsible_party>
  <keyword>adenocarcinoma of the stomach, gastro-esophageal junction or distal esophagus</keyword>
  <keyword>gastric cancer</keyword>
  <keyword>esophageal cancer</keyword>
  <keyword>gastro-esophageal junction</keyword>
  <keyword>docetaxel</keyword>
  <keyword>capecitabine</keyword>
  <keyword>cisplatin</keyword>
  <keyword>perioperative chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

